Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06034275 · ClinicalTrials.gov registry record · Phase 1
Study of VIP943 in Subjects With Advanced CD123+ Hematologic Malignancies
A Phase 1 study of Acute Myeloid Leukemia and B-cell Acute Lymphoblastic Leukemia, sponsored by Vincerx Pharma.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 36
- Enrollment target
- 5
- Study locations
NCT06034275: Recruiting Phase 1 study of Acute Myeloid Leukemia and B-cell Acute Lymphoblastic Leukemia, sponsored by Vincerx Pharma.
NCT06034275 is a Phase 1 study of Acute Myeloid Leukemia and B-cell Acute Lymphoblastic Leukemia that is actively recruiting participants, run by Vincerx Pharma. The registered enrollment target is 36 participants, below the 116-participant average among 306 other Acute Myeloid Leukemia trials with a reported enrollment target (69% lower). The trial reports 5 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06034275, a Phase 1 study of Acute Myeloid Leukemia and B-cell Acute Lymphoblastic Leukemia, is actively recruiting participants, sponsored by Vincerx Pharma.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 36 participants
- Enrollment target
- 5
- Study locations
Study Summary
Dose Escalation - Determine the maximum tolerated dose (MTD), if possible, or minimum optimal biologic dose (OBD), and evaluate the safety and tolerability of VIP943 in subjects with advanced CD123+ hematologic malignancies
Conditions Studied
Interventions
- DRUG VIP943 (QW)
- DRUG VIP943 (BIW)
Study Locations (5)
Alabama
- University of Alabama at Birmingham - Birmingham
Ohio
- University of Cincinnati - Cincinnati
Tennessee
- TriStar Bone Marrow Transplant - Nashville
Texas
- MD Anderson Cancer Center - Houston
Washington
- Fred Hutchinson Cancer Center - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2023-09-13 |
| Est. Completion | 2025-12-31 |
| Phase | Phase 1 |
What NCT06034275 shows while recruiting
NCT06034275 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 36 participants, a relatively small participant target, below the 116-participant average among 306 other Acute Myeloid Leukemia trials with a reported enrollment target (69% lower).
The record links to 3 conditions, with Acute Myeloid Leukemia appearing as the primary indexed condition, and to 2 interventions - of which VIP943 (QW) is the first listed.
NCT06034275 lists 5 locations in 5 states (Alabama, Ohio, Tennessee).
Frequently Asked Questions
What is clinical trial NCT06034275 about?
NCT06034275 is a clinical study titled "Study of VIP943 in Subjects With Advanced CD123+ Hematologic Malignancies". Dose Escalation - Determine the maximum tolerated dose (MTD), if possible, or minimum optimal biologic dose (OBD), and evaluate the safety and tolerability of VIP943 in subjects with advanced CD123+ hematologic malignancies
What is the current status of trial NCT06034275?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 36 participants. The study started on 2023-09-13. Estimated completion is 2025-12-31.
What conditions does trial NCT06034275 study?
This clinical trial studies the following conditions: Acute Myeloid Leukemia, B-cell Acute Lymphoblastic Leukemia, High Risk Myelodysplastic Syndrome.
What interventions are being tested in trial NCT06034275?
The interventions under investigation include: VIP943 (QW) (DRUG), VIP943 (BIW) (DRUG).
Who is sponsoring clinical trial NCT06034275?
This trial is sponsored by Vincerx Pharma, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06034275 being conducted?
This trial has 5 study locations across Alabama, Ohio, Tennessee, Texas, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Acute Myeloid Leukemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06034275's enrollment target sits among peer trials
36 184th of 306 higher than 116 of 306 other Acute Myeloid Leukemia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Acute Myeloid Leukemia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Assess the Safety, Tolerability, and Antileukemic Activity of Debio 1562M in Participants With Acute Myeloid Leukemia (AML)
RECRUITING · Phase 1
-
A Study of CD371-YSNVZIL-18 CAR T Cells in People With Acute Myeloid Leukemia
RECRUITING · Phase 1
-
CPX-351 in Combination With Gemtuzumab Ozogamicin in Newly Diagnosed AML
RECRUITING · Phase 1
-
FHD-286 With Low-Dose Weekly Decitabine/Venetoclax in Patients With Acute Myeloid Leukemia
RECRUITING · Phase 1
-
Testing the Combination of an Anti-Cancer Drug, Iadademstat, With Other Anti-Cancer Drugs (Venetoclax and Azacitidine) for Treating AML
RECRUITING · Phase 1
-
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00929006 · 36 participants · Early Phase 1
Acute Progesterone Suppression of Wake vs. Sleep Luteinizing Hormone Pulse Frequency in Pubertal Girls With and Without Hyperandrogenism
- NCT01891318 · 36 participants · Phase 1
Neoadjuvant Radiosurgery for Resectable Brain Metastases: Phase I/II Study
- NCT02291848 · 36 participants · Phase 1
Tumor-Associated Antigen-Specific Cytotoxic T-Lymphocytes for Multiple Myeloma
- NCT02366819 · 36 participants · Phase 4
Genetic Analysis-Guided Irinotecan Hydrochloride Dosing of mFOLFIRINOX in Treating Patients With Locally Advanced Gastroesophageal or Stomach Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI